Lobe Sciences Stock Price, News & Analysis

Lobe Sciences (OTCQB:LOBEF) announced its participation in the Clusterbusters 20th Annual U.S. Patient Conference from September 11-14, 2025, in Grapevine, Texas. The company will present research on its lead compound, L-130, Conjugated Psilocin™, being developed for chronic cluster headache treatment.

The company recently secured $6 million in funding for its subsidiary Cynaptec Pharmaceuticals, with an investor option for up to $20 million to complete FDA submission of L-130. Lobe aims to engage with patients at the conference to establish a patient advocacy team and design meaningful clinical endpoints.

Lobe Sciences (OTCQB:LOBEF), a clinical stage biopharmaceutical company, has appointed Marco Mastrodonato to its Board of Directors. Mastrodonato brings significant pharmaceutical and biotechnology industry experience, having previously co-founded Sinclair Pharma plc and served as Executive Director of the London Stock Exchange-listed company.

Mastrodonato's extensive background includes founding Metrodora Therapeutics and serving as CEO of BMG Pharma, where he leads development of hyaluronic acid-based technologies. Dr. Fred Sancilio, Lobe Sciences' Chairman and CEO, highlighted their 30-year professional relationship and Mastrodonato's proven success across European and Middle Eastern markets.

Lobe Sciences (OTCQB:LOBEF), a biopharmaceutical company specializing in rare and underserved diseases, has completed its previously announced non-brokered private placement. The company issued 8,535,625 common shares at $0.04 per share, raising total gross proceeds of $341,425 CAD.

The securities issued will be subject to a four-month and one-day statutory hold period. The offering, initially announced on July 29th, was not registered under the U.S. Securities Act and cannot be offered or sold in the United States without registration or an applicable exemption.

Lobe Sciences (OTCQB:LOBEF), a biopharmaceutical company focused on rare and underserved diseases, has announced a non-brokered private placement offering. The company plans to issue up to 8,535,625 common shares at $0.04 CAD per share, aiming to raise gross proceeds of up to $341,425 CAD.

The funds will be utilized for general corporate purposes and working capital needs. The issued securities will be subject to a four-month and one-day holding period and are not registered under the U.S. Securities Act.

Lobe Sciences (OTCQB:LOBEF), a biopharmaceutical company developing therapeutics for rare and underserved diseases, has engaged ArcStone Securities and Investments Corp. for capital markets advisory services. The partnership aims to enhance Lobe's market visibility and institutional investor engagement across North American markets.

Under the agreement, ArcStone will provide comprehensive advisory services including capital markets planning and strategic positioning. The collaboration is effective immediately, with ArcStone's expertise expected to support Lobe's development programs and strengthen its presence in both Canadian and U.S. financial markets.

Lobe Sciences Ltd. (OTCQB:LOBEF), a biopharmaceutical company, has announced a debt settlement through a share issuance. The company has settled an outstanding debt of CAD$11,596.22 owed to Gibbsons P.C. for previous legal services by issuing 546,206 common shares at a deemed price of CAD$0.02123 per share.

The shares were issued on May 13, 2025, and are subject to regulatory hold periods under Canadian securities laws.

Lobe Sciences (OTCQB:LOBEF) has announced the validation of its European Unitary Patent EP4117446 across 17 EU member states for its DHA-based composition targeting Sickle Cell Disease (SCD).

The patent specifically covers Altemia®, a physician-supervised medical food formula designed to address long-chain fatty acid deficiencies in SCD patients. The formulation combines DHA and natural emulsifiers to improve bioavailability and restore red blood cell membrane integrity.

This validation represents a significant expansion of Lobe's intellectual property protection in key European markets, strengthening the company's position for broader commercialization of Altemia®.

Lobe Sciences (LOBEF) has spun out its Conjugated Psilocin™ compound to newly created Cynaptec Pharmaceuticals, securing a $6M investment with an option for additional $20M for Phase 3 trials. Cynaptec will advance the development of this novel psilocin analog, designed to treat chronic cluster headaches without hallucinations. Lobe retains 64% ownership in Cynaptec post-investment. The compound targets an orphan disease affecting 60,000+ US patients with no FDA-approved treatments. Additionally, Lobe is launching Altemia® Medical Food for Sickle Cell Disease, which affects 100,000 people in the US and 10M worldwide, particularly impacting African American children.

Lobe Sciences Ltd. (OTCQB:LOBEF) has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025. Yao brings over 25 years of leadership experience in corporate finance and biotech, having held executive positions at Mountain Valley MD, Scotiabank, and Morgan Stanley. As a co-founder of SelecIn Biomedical Inc., he has experience in developing small molecule therapies and securing early-stage funding. The appointment represents a strategic transition from part-time to full-time financial leadership, aimed at strengthening the company's regulatory compliance, capital markets readiness, and operational expansion. Yao holds an MBA from McGill University, a BS in Biology from Nankai University, and professional designations as FCMA and CGMA.